Lösung
Sponsors
McNeil AB, Janssen - Cilag International, Inmunotek S.L., University Of Cologne
Conditions
EGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerPathologically prevascularized corneas due to herpetic keratopathy prior to “high-risk” corneal transplantation (keratoplasty)Vaping cessation in e-cigarette usersbirch pollen-induced allergic rhinitis
birch pollen-induced allergic rhinoconjunctivitis
Phase 2
A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
RecruitingCTIS2023-505863-35-00
Start: 2024-03-20Target: 15Updated: 2025-10-27
Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)
Not yet recruitingCTIS2025-522099-10-00
Target: 10Updated: 2026-01-28
Phase 3
A Multicenter, Parallel group, Double-blind, Placebo-controlled, Randomized, Efficacy and Safety Study of Nicotine Freshmint Mouthspray in E-cigarette Users Willing to Quit
CompletedCTIS2023-505036-35-00
Start: 2024-04-23End: 2025-12-22Target: 200Updated: 2025-11-19
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescents and adults with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
CompletedCTIS2024-515717-17-00
Start: 2024-10-28End: 2025-06-27Target: 360Updated: 2025-08-07